1、邵毅. 国际干眼新共识(TFOS DEWSⅡ)解读[ J]. 眼科新进展,
2018, 38(1): 1-12.
SHAO Y. Interpretation of TFOS DEWS Ⅱ[ J]. Recent Advances in
Ophthalmology, 2018, 38(1): 1-12.邵毅. 国际干眼新共识(TFOS DEWSⅡ)解读[ J]. 眼科新进展,
2018, 38(1): 1-12.
SHAO Y. Interpretation of TFOS DEWS Ⅱ[ J]. Recent Advances in
Ophthalmology, 2018, 38(1): 1-12.
2、Mizoguchi S, Iwanishi H, Arita R, et al. Ocular surface inflammation
impairs structure and function of meibomian gland[ J]. Exp Eye Res,
2017, 163: 78-84.Mizoguchi S, Iwanishi H, Arita R, et al. Ocular surface inflammation
impairs structure and function of meibomian gland[ J]. Exp Eye Res,
2017, 163: 78-84.
3、Ralph RA, Doane MG, Dohlman CH. Clinical experience with a
mobile ocular perfusion pump[ J]. Arch Ophthalmol, 1975, 93(10):
1039-1043.Ralph RA, Doane MG, Dohlman CH. Clinical experience with a
mobile ocular perfusion pump[ J]. Arch Ophthalmol, 1975, 93(10):
1039-1043.
4、Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears
made with autologous serum in patients with keratoconjunctivitis
sicca[ J]. Arthritis Rheum, 1984, 27(4): 459-461.Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears
made with autologous serum in patients with keratoconjunctivitis
sicca[ J]. Arthritis Rheum, 1984, 27(4): 459-461.
5、Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface
diseases[ J]. Br J Ophthalmol, 2016, 100(1): 22-27.Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface
diseases[ J]. Br J Ophthalmol, 2016, 100(1): 22-27.
6、Giannaccare G, Versura P, Buzzi M, et al. Blood derived eye drops for
the treatment of cornea and ocular surface diseases[ J]. Transfus Apher
Sci, 2017, 56(4): 595-604.Giannaccare G, Versura P, Buzzi M, et al. Blood derived eye drops for
the treatment of cornea and ocular surface diseases[ J]. Transfus Apher
Sci, 2017, 56(4): 595-604.
7、Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: role
in tissue maintenance, wound healing, and ocular pathology[ J]. Ocul
Surf, 2007, 5(3): 228-239.Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: role
in tissue maintenance, wound healing, and ocular pathology[ J]. Ocul
Surf, 2007, 5(3): 228-239.
8、Mandi? JJ, Kozmar A, Kusa?i?-Kuna S, et al. The levels of 12 cytokines
and growth factors in tears: hyperthyreosis vs euthyreosis[ J]. Graefes
Arch Clin Exp Ophthalmol, 2018, 256(4): 845-852.Mandi? JJ, Kozmar A, Kusa?i?-Kuna S, et al. The levels of 12 cytokines
and growth factors in tears: hyperthyreosis vs euthyreosis[ J]. Graefes
Arch Clin Exp Ophthalmol, 2018, 256(4): 845-852.
9、邵毅. 血清滴眼液治疗严重眼表疾病: 英国皇家科学院临床规
范指南解读[ J]. 眼科新进展, 2020, 40(2): 101-104.
SHAO Y. Interpretation of guidelines for clinical standards of RCO
serum eye drops in treatment of severe ocular surface diseases[ J].
Recent Advances in Ophthalmology, 2020, 40(2): 101-104.邵毅. 血清滴眼液治疗严重眼表疾病: 英国皇家科学院临床规
范指南解读[ J]. 眼科新进展, 2020, 40(2): 101-104.
SHAO Y. Interpretation of guidelines for clinical standards of RCO
serum eye drops in treatment of severe ocular surface diseases[ J].
Recent Advances in Ophthalmology, 2020, 40(2): 101-104.
10、Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for
dry eye[ J]. Cochrane Database Syst Rev, 2017, 2(2): Cd009327.Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for
dry eye[ J]. Cochrane Database Syst Rev, 2017, 2(2): Cd009327.
11、Hwang J, Chung SH, Jeon S, et al. Comparison of clinical efficacies of
autologous serum eye drops in patients with primary and secondary
Sj?gren syndrome[ J]. Cornea, 2014, 33(7): 663-667.Hwang J, Chung SH, Jeon S, et al. Comparison of clinical efficacies of
autologous serum eye drops in patients with primary and secondary
Sj?gren syndrome[ J]. Cornea, 2014, 33(7): 663-667.
12、Marks DC, van der Meer PF. Serum eye drops: a survey of international
production methods[ J]. Vox Sang, 2017, 112(4): 310-317.Marks DC, van der Meer PF. Serum eye drops: a survey of international
production methods[ J]. Vox Sang, 2017, 112(4): 310-317.
13、Liu Y, Hirayama M, Cui X, et al. Effectiveness of autologous serum
eye drops combined with punctal plugs for the treatment of Sj?gren
syndrome-related dry eye[ J]. Cornea, 2015, 34(10): 1214-1220.Liu Y, Hirayama M, Cui X, et al. Effectiveness of autologous serum
eye drops combined with punctal plugs for the treatment of Sj?gren
syndrome-related dry eye[ J]. Cornea, 2015, 34(10): 1214-1220.
14、Torricelli AA, Santhanam A, Wu J, et al. The corneal fibrosis response
to epithelial-stromal injury[ J]. Exp Eye Res, 2016, 142: 110-118.Torricelli AA, Santhanam A, Wu J, et al. The corneal fibrosis response
to epithelial-stromal injury[ J]. Exp Eye Res, 2016, 142: 110-118.
15、张梦瑶, 汪水风, 邵毅. 干眼的再生疗法研究进展[ J]. 眼科新进
展, 2019, 39(12): 1192-1196.
ZHANG MY, WANG SF , SHAO Y. Regenerative
medicine in dry eye[ J]. Recent Advances in Ophthalmology, 2019, 39
(12) :1192-1196.张梦瑶, 汪水风, 邵毅. 干眼的再生疗法研究进展[ J]. 眼科新进
展, 2019, 39(12): 1192-1196.
ZHANG MY, WANG SF , SHAO Y. Regenerative
medicine in dry eye[ J]. Recent Advances in Ophthalmology, 2019, 39
(12) :1192-1196.
16、Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and
classification report[ J]. Ocul Surf, 2017, 15(3): 276-283.Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and
classification report[ J]. Ocul Surf, 2017, 15(3): 276-283.
17、Baudouin C. The pathology of dry eye[ J]. Surv Ophthalmol, 2001,
45(Suppl 2): S211-S220.Baudouin C. The pathology of dry eye[ J]. Surv Ophthalmol, 2001,
45(Suppl 2): S211-S220.
18、Fischer KR, Opitz A, B?eck M, et al. Stability of serum eye drops after
storage of 6 months[ J]. Cornea, 2012, 31(11): 1313-1318.Fischer KR, Opitz A, B?eck M, et al. Stability of serum eye drops after
storage of 6 months[ J]. Cornea, 2012, 31(11): 1313-1318.
19、Marchand M, Harissi-Dagher M, Germain M, et al. Serum drops
for ocular surface disease: national survey of Canadian cornea
specialists[ J]. Can J Ophthalmol, 2018, 53(3): 266-271.Marchand M, Harissi-Dagher M, Germain M, et al. Serum drops
for ocular surface disease: national survey of Canadian cornea
specialists[ J]. Can J Ophthalmol, 2018, 53(3): 266-271.
20、Tahmaz V, Gehlsen U, Sauerbier L, et al. Treatment of severe chronic
ocular graft-versus-host disease using 100% autologous serum eye drops
from a sealed manufacturing system: a retrospective cohort study[ J].
Br J Ophthalmol, 2017, 101(3): 322-326.Tahmaz V, Gehlsen U, Sauerbier L, et al. Treatment of severe chronic
ocular graft-versus-host disease using 100% autologous serum eye drops
from a sealed manufacturing system: a retrospective cohort study[ J].
Br J Ophthalmol, 2017, 101(3): 322-326.
21、Versura P, Profazio V, Buzzi M, et al. Efficacy of standardized and
quality-controlled cord blood serum eye drop therapy in the healing of
severe corneal epithelial damage in dry eye[ J]. Cornea, 2013, 32(4):
412-418.Versura P, Profazio V, Buzzi M, et al. Efficacy of standardized and
quality-controlled cord blood serum eye drop therapy in the healing of
severe corneal epithelial damage in dry eye[ J]. Cornea, 2013, 32(4):
412-418.
22、Marks DC, Fisher J, Mondy P, et al. Serum eye drop preparation in
Australia: current manufacturing practice[ J]. Transfus Apher Sci, 2015,
53(1): 92-94.Marks DC, Fisher J, Mondy P, et al. Serum eye drop preparation in
Australia: current manufacturing practice[ J]. Transfus Apher Sci, 2015,
53(1): 92-94.
23、Shtein RM, Shen JF, Kuo AN, et al. Autologous serum-based
eye drops for treatment of ocular surface disease: a report by the
american academy of ophthalmology[ J]. Ophthalmology, 2020,
127(1): 128-133.Shtein RM, Shen JF, Kuo AN, et al. Autologous serum-based
eye drops for treatment of ocular surface disease: a report by the
american academy of ophthalmology[ J]. Ophthalmology, 2020,
127(1): 128-133.
24、van der Meer PF, Seghatchian J, Marks DC. Quality standards, safety
and efficacy of blood-derived serum eye drops: A review[ J]. Transfus
Apher Sci, 2016, 54(1): 164-167.van der Meer PF, Seghatchian J, Marks DC. Quality standards, safety
and efficacy of blood-derived serum eye drops: A review[ J]. Transfus
Apher Sci, 2016, 54(1): 164-167.
25、Stenwall PA, Bergstr?m M, Seiron P, et al. Improving the antiinflammatory effect of serum eye drops using allogeneic serum
permissive for regulatory T cell induction[ J]. Acta Ophthalmol, 2015,
93(7): 654-657.Stenwall PA, Bergstr?m M, Seiron P, et al. Improving the antiinflammatory effect of serum eye drops using allogeneic serum
permissive for regulatory T cell induction[ J]. Acta Ophthalmol, 2015,
93(7): 654-657.
26、Na KS, Kim MS. Allogeneic serum eye drops for the treatment of
dry eye patients with chronic graft-versus-host disease[ J]. J Ocul
Pharmacol Ther, 2012, 28(5): 479-483.Na KS, Kim MS. Allogeneic serum eye drops for the treatment of
dry eye patients with chronic graft-versus-host disease[ J]. J Ocul
Pharmacol Ther, 2012, 28(5): 479-483.
27、Harritsh?j LH, Nielsen C, Ullum H, et al. Ready-made allogeneic ABOspecific serum eye drops: production from regular male blood donors,
clinical routine, safety and efficacy[ J]. Acta Ophthalmol, 2014, 92(8):
783-786.Harritsh?j LH, Nielsen C, Ullum H, et al. Ready-made allogeneic ABOspecific serum eye drops: production from regular male blood donors,
clinical routine, safety and efficacy[ J]. Acta Ophthalmol, 2014, 92(8):
783-786.
28、Lekhanont K, Jongkhajornpong P, Anothaisintawee T, et al. Undiluted
serum eye drops for the treatment of persistent corneal epitheilal defects[ J]. Sci Rep, 2016, 6: 38143.Lekhanont K, Jongkhajornpong P, Anothaisintawee T, et al. Undiluted
serum eye drops for the treatment of persistent corneal epitheilal defects[ J]. Sci Rep, 2016, 6: 38143.
29、Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum
and umbilical cord serum eye drops for dry eye syndrome[ J]. Am J
Ophthalmol, 2007, 144(1): 86-92.Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum
and umbilical cord serum eye drops for dry eye syndrome[ J]. Am J
Ophthalmol, 2007, 144(1): 86-92.
30、Yoon KC, Heo H, Jeong IY, et al. Therapeutic effect of umbilical cord
serum eyedrops for persistent corneal epithelial defect[ J]. Korean J
Ophthalmol, 2005, 19(3): 174-178.Yoon KC, Heo H, Jeong IY, et al. Therapeutic effect of umbilical cord
serum eyedrops for persistent corneal epithelial defect[ J]. Korean J
Ophthalmol, 2005, 19(3): 174-178.
31、Buzzi M, Versura P, Grigolo B, et al. Comparison of growth factor and
interleukin content of adult peripheral blood and cord blood serum eye
drops for cornea and ocular surface diseases[ J]. Transfus Apher Sci,
2018, 57(4): 549-555.Buzzi M, Versura P, Grigolo B, et al. Comparison of growth factor and
interleukin content of adult peripheral blood and cord blood serum eye
drops for cornea and ocular surface diseases[ J]. Transfus Apher Sci,
2018, 57(4): 549-555.
32、Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and efficacy
of autologous plasma rich in growth factors eye drops for the treatment of
evaporative dry eye[ J]. Ophthalmic Res, 2016, 56(2): 68-73.Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and efficacy
of autologous plasma rich in growth factors eye drops for the treatment of
evaporative dry eye[ J]. Ophthalmic Res, 2016, 56(2): 68-73.
33、Versura P, Buzzi M, Giannaccare G, et al. Cord blood serum-based eye
drops: the impact of donor haematological and obstetric factors on the
variability of epidermal growth factor levels[ J]. Blood Transfus, 2014,
12 (Suppl 1): S44-S50.Versura P, Buzzi M, Giannaccare G, et al. Cord blood serum-based eye
drops: the impact of donor haematological and obstetric factors on the
variability of epidermal growth factor levels[ J]. Blood Transfus, 2014,
12 (Suppl 1): S44-S50.
34、Versura P, Buzzi M, Giannaccare G, et al. Targeting growth factor supply
in keratopathy treatment: comparison between maternal peripheral
blood and cord blood as sources for the preparation of topical eye
drops[ J]. Blood Transfus, 2016, 14(2): 145-151.Versura P, Buzzi M, Giannaccare G, et al. Targeting growth factor supply
in keratopathy treatment: comparison between maternal peripheral
blood and cord blood as sources for the preparation of topical eye
drops[ J]. Blood Transfus, 2016, 14(2): 145-151.
35、王玲, 单桂秋,张卫. 富血小板血浆在眼科疾病治疗中的研究进
展[ J]. 中国输血杂志, 2016, 29(6): 568-573.
WANG L, DAN GQ, ZHANG W. Advances in platelet-rich plasma in ophthalmic diseases[ J]. Chinese Journal of Blood
Transfusion, 2016, 29(6): 568-573.王玲, 单桂秋,张卫. 富血小板血浆在眼科疾病治疗中的研究进
展[ J]. 中国输血杂志, 2016, 29(6): 568-573.
WANG L, DAN GQ, ZHANG W. Advances in platelet-rich plasma in ophthalmic diseases[ J]. Chinese Journal of Blood
Transfusion, 2016, 29(6): 568-573.
36、Alio JL, Arnalich-Montiel F, Rodriguez AE. The role of “eye platelet
rich plasma” (E-PRP) for wound healing in ophthalmology[ J]. Curr
Pharm Biotechnol, 2012, 13(7): 1257-1265.Alio JL, Arnalich-Montiel F, Rodriguez AE. The role of “eye platelet
rich plasma” (E-PRP) for wound healing in ophthalmology[ J]. Curr
Pharm Biotechnol, 2012, 13(7): 1257-1265.
37、Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. The effect
of immunologically safe plasma rich in growth factor eye drops in
patients with Sj?gren syndrome[ J]. J Ocul Pharmacol Ther, 2017,
33(5): 391-399.Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. The effect
of immunologically safe plasma rich in growth factor eye drops in
patients with Sj?gren syndrome[ J]. J Ocul Pharmacol Ther, 2017,
33(5): 391-399.
38、Anitua E, de la Fuente M, Riestra A, et al. Preservation of biological
activity of plasma and platelet-derived eye drops after their different
time and temperature conditions of storage[ J]. Cornea, 2015, 34(9):
1144-1148.Anitua E, de la Fuente M, Riestra A, et al. Preservation of biological
activity of plasma and platelet-derived eye drops after their different
time and temperature conditions of storage[ J]. Cornea, 2015, 34(9):
1144-1148.
39、Pezzotta S, Del Fante C, Scudeller L, et al. Long-term safety and efficacy
of autologous platelet lysate drops for treatment of ocular GvHD[ J].
Bone Marrow Transplant, 2017, 52(1): 101-106.Pezzotta S, Del Fante C, Scudeller L, et al. Long-term safety and efficacy
of autologous platelet lysate drops for treatment of ocular GvHD[ J].
Bone Marrow Transplant, 2017, 52(1): 101-106.
40、Zallio F, Mazzucco L, Monaco F, et al. A single-center pilot prospective
study of topical application of platelet-derived eye drops for patients
with ocular chronic graft-versus-host disease[ J]. Biol Blood Marrow
Transplant, 2016, 22(9): 1664-1670.Zallio F, Mazzucco L, Monaco F, et al. A single-center pilot prospective
study of topical application of platelet-derived eye drops for patients
with ocular chronic graft-versus-host disease[ J]. Biol Blood Marrow
Transplant, 2016, 22(9): 1664-1670.
